Medicines Co said the U.S. Food and Drug
Administration approved its injectable blood pressure
The drug will be launched in September.
The drug, which is given intravenously, is designed for
the rapid and precise control of high blood pressure
for critical care in areas such as the emergency room,
operating room, and intensive care unit .
Cleviprex has a rapid onset and offset of action in
determining the smallest amount of concentration
necessary for precise blood pressure control. In
addition, Cleviprex does not accumulate in the body,
as it metabolized in the blood and tissues, which is
different from many current IV hypertension drugs that
are metabolized by the kidney and/or liver.
Cleviprex is an IV dihydropyridine calcium channel
blocker. Six Phase III trials involving 1,406 medical and
surgical patients treated with Cleviprex were the basis
for the first-cycle U.S. approval of the drug. The Phase
III trials met all of their primary endpoints.
New Blood Pressure Medication Receives FDA
Approval Health News 5 August 2008
THIS WEBSITE TALKS ABOUT THE SIDE EFFECTS AND THE POTENTIAL HEALTH BENEFITS OF HERBS, SUPPLEMENTS,